Herba Epimedii: An ancient Chinese herbal medicine in the prevention and treatment of osteoporosis

Current Pharmaceutical Design

Volumn 22, Issue 3, 2016, Pages 328-349

  Wang, Lili ^a   Li, Yu ^a   Guo, Yubo ^a   Ma, Rufeng ^a   Fu, Min ^b   Niu, Jianzhao ^a   Gao, Sihua ^a   Zhang, Dongwei ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Chinese medicine; Clinical trials; Herba epimedii; Osteoporosis; Pharmacology; Phytochemistry

Indexed keywords

HERBA EPIMEDII EXTRACT; HERBACEOUS AGENT; PLANT EXTRACT; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; EPIMEDII FLAVONE;

ARTICLE; BONE DEVELOPMENT; BONE REMODELING; CHINESE HERB; CHINESE MEDICINE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HERBA EPIMEDII; HUMAN; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; PHYTOCHEMISTRY; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; SECONDARY OSTEOPOROSIS; SENILE OSTEOPOROSIS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; EPIMEDIUM; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; EPIMEDIUM; HUMANS; MEDICINE, CHINESE TRADITIONAL; MOLECULAR STRUCTURE; OSTEOPOROSIS;

EID: 84962609978     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151112145907     Document Type: Article

References (145)

1. Gerdhem P. Osteoporosis and fragility fractures: Vertebral fractures. Best Pract Res Clin Rheumatol 2013; 27: 743-55.
2. Bone HG, Dempster DW, Eisman JA, et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int 2015; 26: 699-712.
3. Pharmacopoeia of the People's Republic of China. Beijing: China Medical Science Press 2010.
4. Li C, Li Q, Mei Q, Lu T. Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii. Life Sci 2015; 126: 57-68.
5. Liu R, Kang X, Xu L, et al. Effect of the combined extracts of herba epimedii and fructus ligustri lucidi on sex hormone functional levels in osteoporosis rats. Evid Based Complement Alternat Med 2015; 2015: 184802.
6. Ye XB. Clinical observation of therapy of tonifying kidney and strengthening bone for treatment of glucocorticoid-induced osteoporosis in systemic lupus erythematosus. J Guangzhou University of Traditional Chine Med 2014; 21: 369-74.
7. Zhen WJ, Pan JX, Fang JQ. 50 cases of clinical observation on effect of Gubi decoction combined with western medicine on osteoporosis. J New Chinese Med 2014; 46: 103-5.
8. Liu WY. Yanghe tang treat 65 cases of senile primary osteoporosis. TCM Res 2013; 18: 35-7.
9. Zhang WY, Chen MY. Clinical observation on the effect of Wenshen Zhuanggu decoction on primary osteoporosis. Jilin J Traditional Chinese Med 2011; 31: 650-2.
10. Wang H, Yan XP, Kong WP, Lu P, Luo W, Liu HM. Effect of Bushen Qiangdu Recipe on Osteoporosis and Bone Loss of Patients with Ankylosing Spondylitis. Chinese J Integr Traditional Western Med 2011; 31: 471-5.
11. Hu XY, Li XF. Clinical research on treating senile osteoporosis veterbrate compression with Zhuanggu decoction. Clin J Chinese Med 2014; 6: 3.
12. Zheng X, Shi YW, Li JL, Hu X. The effect of Jianggukang capsule on 42 cases of postmanulpause osteoporosis. Shan Xi Zhong Yi 2008; 28: 1178-9.
13. Xin XG, Qiu B, Tian DX, Tan YJ. Clinical observation on the effect of Gukang pill in 30 patients with primary osteoporosis Shan Xi Zhong Yi 2009; 30: 436-7.
14. Zhang CA. Treating 30 cases of primarry osteoporosis with Cangyao Silu wenshen capsule in clinic. Shan Xi Zhong Yi 2009; 30: 1619-21.
15. Zhou ZK, Ceng HB. J.J. Q, Chen C. Clinical effect of Huangqi Sanxian decoction on postmanupausal osteoporosis. New J Triditional Chinese Med 2006; 38: 40-1.
16. Xu ZM, Zhou ZK. Clnical study the influences of Huangqi Sanxian decoction on BMD and BMC in postmanupausal osteoporosis. Shenzhen J Integrated Traditional Chinese Western Med 2009; 19: 84-6.
17. Liu H. Clinical effect of Er'xian decotion on treating primarry osteoporosis. Contemporary Med Forum 2014; 12: 2.
18. Wu F, Cai LX, Chen JR, Wang G. Clinical Efficacy of Jiaweierxian Granule Treatment on Postmenopausal Women with Osteoporosis. J GanNan Med University 2014; 34: 360-4.
19. Chen XY. Treatment of Postmenopausal Osteoporosis by Gubao Mixture: A Clinical Observation of 40 Cases. New J Traditional Chinese Med 2004; 36: 32-4.
20. Sun WS. Treatment of Senile Osteoporosis with Guwei Decoction: A Clinical Observation of 50 Cases. Si Chuan Zhong Yi 1995: 32-3.
21. Wang J, Wu P, Guo Z, et al. Clincial Study of the effect of Guwei Formulor on Bone Metabolism Markers on Senile Uyghur Women. Xinjiang J Traditional Chinese Med 2014; 32: 7-9.
22. Qin LM, Gao JL. Clinical study of loose bone soup combined with alendronate in treatment of 30 cases with the spleen and kidney insufficiency type osteoporosis. Chinese Community Doctors 2014; 42: 85-6.
23. Huang JX, Zhang HC, He WZ, Kong WH, Dai LP, Ye ZZ. Clinical observation of gusongbao combined with caltrate D in the treatment of patients with osteopenia and osteoporosis. Hainan Med J 2013; 24: 1898-91.
24. Huang YM, Xu SJ, Shi YX, Liu JW, Yang WY. Treatment of Postmanupausal Osteoporosis by Gusong'an Capasule: A clinical Observation of 30 cases. Shan Xi Zhong Yi 2006; 27: 954-6.
25. Pei Y. Clinical study of gusongbao capsule combined with acupuncture in the treatment of osteoporosis. Asia Pacific Traditional Med 2014; 10: 123-4.
26. Zhou ZG, An JW, Zhang GY. Treatment of osteoporosis fractures with shuanggu decoction: a cilinical observations of 48 cases. Shan Xi Zhong Yi 2006; 27: 1503-4.
27. Zhang YP, Cui YH, Kang HZ, Zhang B. Clinical obeservations on the effect of shiguyin on bone formation and destruction in postmanulpausal osteoporosis. J New Chinese Med 2007; 39: 30-1.
28. Gao YH, Mei TC, Mei JH. Clinical obsercations of jinlong pill in the treatment of osteoporosis induced low back pain. Zhong Yi Yao Xin Xi 2005; 22: 29.
29. He XQ. Clincal observation of the influences of bushen yangxue decoction on BMD in postmanulpausal osteoporosis. New J Traditional Chinese Med 2006; 38: 42-3.
30. Zhou B. Clinical observation of modified six ingredient rehmannia decoction in the treatment of menopausal osteoporosis. Chinese Foreign Med Res 2014; 28: 1-2.
31. Chen Y, Ye Z, Guan H, Liang J. Treatment of inflammation induced enteropathy with osteoporosis by jianpi yishen formulations: a 96-cases clinical observations. Nei Meng Gu Zhong Yi Yao 2014; 28-9.
32. He B, Hao J, Cai HY, Hao H. Treatment of senile osteoporosis by Liu Dou Ye formulor: A 38-case clinical observation. Chinese J Traditional Med Sceidence Technol 2014; 29: 595.
33. Zhong Y Q.G.M. P, Deng WM, Zhang GC. Clinical study of Gushen Yijingtang (GSYJT) on the treatment of primary osteoporosis of deficiency in kidney yang. Chinese J Traditional Med Traum Orthop 2007: 1724-5.
34. Ji B, Guan J, Chen XM, et al. Clinical research of self-made kidneytonifying and blood circulation promoting chinese medicine in patients with diabetic osteoporosis. Guide China Med 2012; 10: 3-4.
35. Chai Y, Li Q, Liu F, Wen Z, Yang J. Clinical observation of the effect of bushen huoxue formulor in the treatment of senile women osteoporosis. Chinese J Clin Resent Drug Use 2015; 8: 83-4.
36. Deng MM. Clinical observation of the effect of yishen zhuanggu formulor on type 2 diabetes induced osteoporosis. J Guiyang College Traditional Chinese Med 2013; 35: 58-9.
37. Zhang XJ, Nie J. Clinical effect of Bu sheng-huo xue capsules in treatment of osteoporosis pain of aged males. Prog Pharm Sci 2009; 06: 274-6.
38. Zhang J.Q. F, Wang XG. Clinical study on the effect of bushen jianpi decoction in the treatment of primary osteoporosis. J China Prescription Drug 2014; 12: 112-3.
39. Li Y, Cai WP, Hu YW, Xu ZX. An Manhong.clinical observation on post-menopause osteoporosis treated with yiguyin. J Zhejiang College Traditional Chinese Med 2009; 33: 53-4.
40. Ding WQ. Clinical observation of Xian'gu decction combined with calcitrate D tablet in the treatment of postmenopausal hip osteoporosis. J New Chinese Med 2011; 43: 89-90.
41. Pan WJ, Ceng SM, Huang HX. Clinical observation of the effect of bushen yijing method in the treatment of postmenopausal osteoporosis. J Shanxi Coll Traditional Chinese Med 2006; 7: 30-1.
42. Liu GG, Zhang LJ, Huang LJ. Treatment of postmenopausal osteoporosis by cishen gukang pill: a 30-case clinical study. Henan Traditional Chinese Med 2013; 33: 2011-2.
43. Liu JM, Xue L, Tian DX. Clinical research of primary osteoporosis treated with gukang tablets. World J Integr Traditional Western Med 2012; 04: 323-5.
44. Peng J, Li WY, Li HP, Xian XL, Lu YQ, Deng CL. The study on cli nical effect of Bushen Jian' gu recipe in the treatment of osteoporotic vertebral fracture. China Pratice Med 2013; 8: 42-4.
45. Lin SF, Pan FW, Liu YJ, et al. Treatment of bushen jiangu decoction on 50 cases with primary osteoporosis. Chinese J Exp Traditional Med Formulae 2014; 20: 192-5.
46. Lu ZS. Assistant therapy of osteoporotic compression fracture by bushen jian'gu decoction: a 46-case clinical observation. Guiding J Traditional Chinese Med Pharm 2012; 18: 51-2.
47. Meng T, Li L. Treatment of 50 case of osteoprorosis by bushen jian'gu formulae. J Sichuan Traditional Chinese Med 2013; 31: 116-7.
48. Zou L, Huang HG, Ye Z, et al. Comparison of therapeutic effects between bushen zhuanggu granules and alendronate sodium on osteoporosis of elderly male patients. Military Med J South China 2013; 32: 730-4.
49. Gong RX. Effects of Kang Gu Zhi Zeng Sheng Capsule as a novel candidate for treatment of primary osteoporosis: a clinical trial. J Taishan Med College 2014; 35: 146-9.
50. Xu ST, Xie W, Tan L. Clinical observation of the effect of kang guzhi shusong pill on the treatment of osteoporosis. Chinese J Integrated Traditional Western Med 2013; 33: 1427-9.
51. Huang GB. The application of zhuanggu qiangjin tablets in the treatment of primary osteoporosis with deficiencen in liver and kidney. J New Chinese Med 2014; 46: 86-8.
52. Wen L, Qi L, Chen PG, Luo WX. Clinical study of the effect of jianpi yanggu decoction cpmbined with warming needle on osteoporosis. J Changchun Univ Traditional Chinese Med 2011; 27: 533-4.
53. Wang HM, Ge JM, Zhu HM, et al. Summary of clinical trials on qigu capsule in treating primary osteoporosis. Chinese J Traditional Med Traumatol Orthoped 2010; 18: 12-5.
54. Zhang ZQ, Yan LP, Wei YH, Zhang HM. The efficacy observation of wenshen zhuyu zhuanggu decoction in treating primary kidney deficinecy and stasis osteoporosis: A 84-case study. Hebei J Traditional Chinese Med 2013; 35: 683-4.
55. Gao MS. Clinical observation of tangmaikang granules combined with alendronate sodium tablets in the treatment of bone metabolism in elderly patients with type 2 diabetes. China Pharm 2012; 23: 2658-60.
56. Lin XG, Zeng ZM, Pan GG. Clinical observation of wenyang bushen decoction for treatment of sennile osteoporosis with kidney Yang deficiency: a report of 42 cases. J New Chinese Med 2013; 45: 88-90.
57. Diao W, Yu J, Chen J, Li T, Huang B. Effect of yangxue gushen decoction on pain score and bone mineral density of women with postmenopausal osteoporosis. J New Chinese Med 2013; 45: 3.
58. Cui SK. Treatment of 30 cases of primary osteoporosis with yiqi yangxue recipe. Global Traditional Chinese Med 2013; 6: 281-3.
59. Li L, Ding LJ, Wang Y, Feng WW. Clinical research on yishen guben decoction in treatment with senile osteoporosis. Chinese J Guang Ming Traditional Chinese Med 2013; 28: 1843-5.
60. Huang XJ. Clinical observation of bugu decoction for treatment of senile osteoporosis with low back pain. Maternal Child Health Care China 2013; 28: 4990-1.
61. Wang XD, Deng WM, Hong MJ, Liu F, Wang Q, Sun PH. Clinical study of hugu capasule for the treatment of postmenopausal osteoporosis. J Pract Med 2011; 27: 1662-5.
62. Du YB, Wu Y.Y.R. D, Xie CQ. Clinical observation of gushu granule for treating postmenopausal osteoporosis. J New Chinese Med 2013; 45: 76-8.
63. Wu JR, Lian F, Sun ZG. Clinical study of gugu granule for treating postmenopausal osteoporosis. J Shandong Traditional Chinese Med 2009; 33: 388-9.
64. Su YB, Li MX, Lin YF, et al. Clinical efficacy of qianggu huoxue deccoction for treating primary osteoporosis with distal radius fracture. J Traditional Chinese Orthoped Traumatol 2008; 20: 17-8.
65. Yang JP, Wang JB, Ding CG, Huo ST. Clinical study of gushibao capasule for treating osteoporosis. Hebei J Traditional Chinese Med 2007; 29: 299-301.
66. Wang JM. The clinical research on how chinese herbal medicinegushutong affects 83 patients who have the osteoporosis after the menopause. Chinese J Traditional Med Traumatol Orthoped 2007; 15: 2.
67. Xing WZ, Gao Y, Yin YH, Shi W. Clinical efficacy of kidney-warming and bone strengthening prescription combined with caltrate D in the treatment of postmenopausal osteoporosis: a report of 28 cases. Hunan J Traditional Chinese Med 2014; 30: 5-7.
68. Guo Y, Li Y, Xue L, et al. Salvia miltiorrhiza: an ancient Chinese herbal medicine as a source for anti-osteoporotic drugs. J Ethnopharmacol 2014; 155: 1401-16.
69. Leung PC, Siu WS. Herbal treatment for osteoporosis: a current review. J Tradit Complement Med 2013; 3: 82-7.
70. Tantry MA, Dar JA, Idris A, Akbar S, Shawl AS. Acylated flavonol glycosides from Epimedium elatum, a plant endemic to the Western Himalayas. Fitoterapia 2012; 83: 665-70.
71. Wang JX, Fan XW, Lu XM, Niu JF, Zhu R. Chemical Constituents of Epimedium platyetalum. Acta Botanica Sbtwa 2002; 44: 1258-60.
72. Yang L, Wang NL, Cai GP. Maohuoside A promotes osteogenesis of rat mesenchymal stem cells via BMP and MAPK signaling pathways. Mol Cell Biochem 2011; 358: 37-44.
73. Wang MQ, Peng X, Gan QF. Studies on chemical constituents of epimedium brevicornum maxim. Res Practise Chinese Med 2005: 39-42.
74. Li YB, Meng FH, Lu XM, Li FM. Chemical constituents from herb of Epimedium brevicornum. Zhongguo Zhong Yao Za Zhi 2005; 30: 586-8.
75. Wang T, Zhang DW, Zhang JC, Yang MS, Xiao PG. Isolation and identification of flavonoids from Epimedium koreanum and their effects on proliferation of RAW 26417 cell line. Chinese Traditional Herbal Drugs 2006; 37: 1458-62.
76. Yang Y, Zhang HJ, Zhu ZH, He HH. Studies on the chemical constituents of epimedium brevicornum. J Chinese Med Mater 2009; 32: 1051-3.
77. Chen BL, Xie DH, Wang ZW, Li FB, Xu DL, Li YQ. Effect of total flavone of Epimedium on expression of bone OPG, OPGL mRNA in ovariectomized rats. Zhongguo Gu Shang 2009; 22: 271-3.
78. Li J, Song M, Luo X, Xie XW. Effects of total flavonoids of epimedium on biodynamics and bone morphological metrology of ovariectomized rats. Western J Traditional Chinese Med 2014: 13-5.
79. Zhan Y, Wei YJ, Wang CM, Sun E, Jia XB. Preventive effect of totol flavonoids of Epimedii Folium on the zebrafish osteoporosis model induced by prednisolone. Chin Hosp Pharm J 2014: 251-255.
80. Chen WF, Mok SK, Wang XL, et al. Total flavonoid fraction of the Herba epimedii extract suppresses urinary calcium excretion and improves bone properties in ovariectomised mice. Br J Nutr 2011; 105: 180-9.
81. Gao SG, Cheng L, Li KH, et al. Effect of epimedium pubescen flavonoid on bone mineral status and bone turnover in male rats chronically exposed to cigarette smoke. BMC Musculoskelet Disord 2012; 13: 105.
82. Xie F, Wu CF, Lai WP, et al. The osteoprotective effect of Herba epimedii (HEP) extract in vivo and in vitro. Evid Based Complement Alternat Med 2005; 2: 353-61.
83. Zhang Wei LJ, Song Min, Xie Xing-wen, Zhang Yan-jun. Influence of total flavonoids from yinyanghuo on calcium and phosphorus metabolism of emasculate rat. Western J Traditional Chinese Med 2012: 3.
84. Bonjour JP. Calcium and phosphate: a duet of ions playing for bone health. J Am Coll Nutr 2011; 30: 438S-48S.
85. Omoigui S. The Interleukin-6 inflammation pathway from cholesterol to aging--role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases. Immun Ageing 2007; 4: 1.
86. Wu MS, Zhao SZ, Ren LZ. Effects of total flavonoids of Epimedium sagittatum on the mRNA expression of the estrogen receptor _ and _ in hypothalamus and hippocampus in ovariectomized rats. J Cent South Univ (Med Sci) 2011: 15-20.
87. Liu ZQ, Song M, Jiang YW, Lei B. Experimental study on the effect of icariin on serum PINP,NTx in OVX rats. J Gansu Coll TCM 2014; 31: 4-7.
88. Qian G, Zhang X, Lu L, Wu X, Li S, Meng J. Regulation of Cbfa1 expression by total flavonoids of Herba epimedii. Endocr J 2006; 53: 87-94.
89. Cheng K, Ge BF, Zhen P, et al. Effects of icariin and genistein on peak bone mass in rats. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2013; 35: 542-6.
90. Bao JR, Yang JW, Li SF, Zhao W, Zhang QL, Yan YQ. Effects of Icariin on ovariectomized osteoporotic rats. J Hyegiene Res 2005; 34: 191-3.
91. Li XF, Xu H, Zhao YJ, et al. Icariin augments bone formation and reverses the phenotypes of osteoprotegerin-deficient mice through the activation of Wnt/ beta-catenin-BMP signaling. Evid Based Complement Alternat Med 2013; 2013: 652317.
92. Bian Q, Huang JH, Liu SF, et al. Different molecular targets of Icariin on bMSCs in CORT and OVX-rats. Front Biosci (Elite Ed) 2012; 4: 1224-36.
93. Zhu GZ, Liu MY, Sun LF, Cai Z, Song XH. Effect of icariin on osteoporosis induced by retinoic acid in rats. Hebei Med J 2014; 36: 8-10.
94. Nian H, Ma MH, Nian SS, Xu LL. Antiosteoporotic activity of icariin in ovariectomized rats. Phytomedicine 2009; 16: 320-6.
95. Xue L, Wang Y, Jiang Y, et al. Comparative effects of er-xian decoction, epimedium herbs, and icariin with estrogen on bone and reproductive tissue in ovariectomized rats. Evid Based Complement Alternat Med 2012; 2012: 241416.
96. Ouyang L, Zhang Q, Ruan X, Feng Y, Wang X. Treatment effect of extract on postmenopausal osteoporosis. Exp Ther Med 2014; 7: 1687-90.
97. Wen Y, Zhang JJ, Chen XM, Ren GY, Zhang GL. Effects of icariin of examining the expression level of interleukin 6 in mice models of experimental osteoporosis. Guizhou Med J 2010: 781-3.
98. Li GW, Xu Z, Chang SX, Nian H, Wang XY, Qin LD. Icariin prevents ovariectomy-induced bone loss and lowers marrow adipogenesis. Menopause 2014; 21: 1007-16.
99. Wang F, Liu Z, Lin S, Lu H, Xu J. Icariin enhances the healing of rapid palatal expansion induced root resorption in rats. Phytomedicine 2012; 19: 1035-41.
100. Liu YJ, Feng W, He DY, Wang QQ. Effect of icariin on bone destruction and serum RANKL/OPG levels in type II collageninduced arthritis rats. Zhongguo Zhong Xi Yi Jie He Za Zhi 2013; 33: 1221-5.
101. Schluesener JK, Schluesener H. Plant polyphenols in the treatment of age-associated diseases: revealing the pleiotropic effects of icariin by network analysis. Mol Nutr Food Res 2014; 58: 49-60.
102. Feng R, Feng L, Yuan Z, et al. Icariin protects against glucocorticoid-induced osteoporosis in vitro and prevents glucocorticoidinduced osteocyte apoptosis in vivo. Cell Biochem Biophys 2013; 67: 189-97.
103. Wong KC, Lee KS, Luk HK, et al. Er-xian Decoction exerts estrogen-like osteoprotective effects in vivo and in vitro. Am J Chin Med 2014; 42: 409-26.
104. Zhang DW, Cheng Y, Wang NL, Zhang JC, Yang MS, Yao XS. Effects of total flavonoids and flavonol glycosides from Epimedium koreanum Nakai on the proliferation and differentiation of primary osteoblasts. Phytomedicine 2008; 15: 55-61.
105. Liu Y, Zang H, Zhang H, Chen J. Effect of Herba Epimedii Flavone on expression of OPG and RANKL in rat osteoblasts. Zhong Yao Cai 2005; 28: 1076-8.
106. Ma HP, Ma XN, Ge BF, et al. Icariin attenuates hypoxia-induced oxidative stress and apoptosis in osteoblasts and preserves their osteogenic differentiation potential in vitro. Cell Prolif 2014; 47: 527-39.
107. Zhai YK, Guo XY, Ge BF, et al. Icariin stimulates the osteogenic differentiation of rat bone marrow stromal cells via activating the PI3K-AKT-eNOS-NO-cGMP-PKG. Bone 2014; 66: 189-98.
108. Luo Z, Liu M, Sun L, Rui F. Icariin recovers the osteogenic differentiation and bone formation of bone marrow stromal cells from a rat model of estrogen deficiency-induced osteoporosis. Mol Med Rep 2015.
109. Zhai Y, Ge B, Ma H, et al. Icariin promotes osteogenic differentiation of rat bone marrow stromal cells in vitro. Zhongguo ZhongYao ZaZhi 2010; 35: 3219-22.
110. Zhang JF, Li G, Chan CY, et al. Flavonoids of Herba Epimedii regulate osteogenesis of human mesenchymal stem cells through BMP and Wnt/beta-catenin signaling pathway. Mol Cell Endocrinol 2010; 314: 70-4.
111. Chen KM, Ma HP, Ge BF, et al. Icariin enhances the osteogenic differentiation of bone marrow stromal cells but has no effects on the differentiation of newborn calvarial osteoblasts of rats. Pharmazie 2007; 62: 785-9.
112. Chen KM, Ge BF, Ma HP, Liu XY, Bai MH, Wang Y. Icariin, a flavonoid from the herb Epimedium enhances the osteogenic differentiation of rat primary bone marrow stromal cells. Pharmazie 2005; 60: 939-42.
113. Wu H, Zha ZG, Yao P. Experimental study of icariin in inducing bone marrow mesenchymal stem cell differentiation. Zhongguo Zhong Xi Yi Jie He Za Zhi 2010; 30: 410-5.
114. Zhang JF, Li G, Meng CL, et al. Total flavonoids of Herba Epimedii improves osteogenesis and inhibits osteoclastogenesis of human mesenchymal stem cells. Phytomedicine 2009; 16: 521-9.
115. Xiao Q, Chen A, Guo F. Effects of Icariin on expression of OPN mRNA and type I collagen in rat osteoblasts in vitro. J Huazhong Univ Sci Technol Med Sci 2005; 25: 690-2.
116. Zhai YK, Li ZZ, Chen KM, Zhang N, Cheng GZ, Zhu RQ. Effects of icariin on the proliferation, differentiation and maturation of rat calvarial osteoblasts in vitro. Zhong Yao Cai 2011; 34: 917-22.
117. Ma HP, Ming LG, Ge BF, et al. Icariin is more potent than genistein in promoting osteoblast differentiation and mineralization in vitro. J Cell Biochem 2011; 112: 916-23.
118. Cai M, Li G, Tao K, et al. Maohuoside A acts in a BMP-dependent manner during osteogenesis. Phytother Res 2013; 27: 1179-84.
119. Wu Y, Xia L, Zhou Y, Xu Y, Jiang X. Icariin induces osteogenic differentiation of bone mesenchymal stem cells in a MAPKdependent manner. Cell Prolif 2015; 48: 375-84.
120. Song L, Zhao J, Zhang X, Li H, Zhou Y. Icariin induces osteoblast proliferation, differentiation and mineralization through estrogen receptor-mediated ERK and JNK signal activation. Eur J Pharmacol 2013; 714: 15-22.
121. Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 2004; 26: 179-84.
122. Shapses SA, Cifuentes M, Spevak L, et al. Osteopontin facilitates bone resorption, decreasing bone mineral crystallinity and content during calcium deficiency. Calcif Tissue Int 2003; 73: 86-92.
123. Song M, Luo X.N. L, Li J. Effects of drug-containing serum of total flavone of epimedium on expression of OPG/OPGL gene osteoblasts. LiIShiZhen Med Mater Med Res 2012: 883-6.
124. Ding HL, Wu YS, Lin Y, Lin YP. Changes with age and effect of Icariin on genetic expression of RANKL-OPG in Rats Osteoblasts. Zhong Yi Zheng Gu 2010; 22: 7-10.
125. Jia W. Post-absorption/metabolism multicompound drug: a new approach to modernization of Chinese herbal medicine. J Chinese Integrative Med 2006; 4: 4.
126. Song LG, Zhang XZ, Zhao JS, et al. Signal pathway involved in regulation of Cbfa1 expression in osteoblasts by icariin Chin J Endocrinol Metab 2010: 489-93.
127. Li LH, Ding DF, Du GQ, Y.S, Shi YS, Zhan HS. Effect of Icariin on osteoblast proliferation and expression of alkaline phosphatase and Runx2 protein in rats. Orthop J China 2013; 21: 2195-9.
128. Hsieh TP, Sheu SY, Sun JS, Chen MH, Liu MH. Icariin isolated from Epimedium pubescens regulates osteoblasts anabolism through BMP-2, SMAD4, and Cbfa1 expression. Phytomedicine 2010; 17: 414-23.
129. Liang W, Lin M, Li X, et al. Icariin promotes bone formation via the BMP-2/Smad4 signal transduction pathway in the hFOB 1.19 human osteoblastic cell line. Int J Mol Med 2012; 30: 889-95.
130. Yin XX, Chen ZQ, Liu ZJ, Ma QJ, Dang GT. Icariine stimulates proliferation and differentiation of human osteoblasts by increasing production of bone morphogenetic protein 2. Chin Med J (Engl) 2007; 120: 204-10.
131. Hsieh TP, Sheu SY, Sun JS, Chen MH. Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NFkappaB regulated HIF-1alpha and PGE(2) synthesis. Phytomedicine 2011; 18: 176-85.
132. Xiao HH, Fung CY, Mok SK, et al. Flavonoids from Herba epimedii selectively activate estrogen receptor alpha (ERalpha) and stimulate ER-dependent osteoblastic functions in UMR-106 cells. J Steroid Biochem Mol Biol 2014; 143: 141-51.
133. Meng FH, Li YB, Xiong ZL, Jiang ZM, Li FM. Osteoblastic proliferative activity of Epimedium brevicornum Maxim. Phytomedicine 2005; 12: 189-93.
134. Mok SK, Chen WF, Lai WP, et al. Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. Br J Pharmacol 2010; 159: 939-49.
135. Cao H, Ke Y, Zhang Y, Zhang CJ, Qian W, Zhang GL. Icariin stimulates MC3T3-E1 cell proliferation and differentiation through up-regulation of bone morphogenetic protein-2. Int J Mol Med 2012; 29: 435-9.
136. Yang L, Lu D, Guo J, Meng X, Zhang G, Wang F. Icariin from Epimedium brevicornum Maxim promotes the biosynthesis of estrogen by aromatase (CYP19). J Ethnopharmacol 2013; 145: 715-21.
137. Chen KM, Ge BF, Liu XY, et al. Icariin inhibits the osteoclast formation induced by RANKL and macrophage-colony stimulating factor in mouse bone marrow culture. Pharmazie 2007; 62: 388-91.
138. Lv MB, Chen KM, Ge BF. Effect of icariin on the expression of MMP-9 and Cathepsin K mRNA in mouse osteoclasts. Chin J Osteoporos 2014; 20: 896-9.
139. Zhang DW, Cheng Y, Zhang JC, Wang NL, Yang MS, Yao XS. Effects of icariin on the differentiation and bone resorption function of osteoclasts. Chinese Pharmacol Bull 2007; 23: 463-6.
140. Zhang D, Zhang J, Fong C, Yao X, Yang M. Herba epimedii flavonoids suppress osteoclastic differentiation and bone resorption by inducing G2/M arrest and apoptosis. Biochimie 2012; 94: 2514-22.
141. Yang QX, Liu YQ, Wang L, Xiao HB. Screening of bioactive components in epimedium for osteoporosis treatment by model population analysis. Acta Pharm Sin 2012; 47: 1205-9.
142. Liu YQ, Yang QX, Cheng MC, Xiao HB. Synergistic inhibitory effect of Icariside II with Icaritin from Herba Epimedii on preosteoclastic RAW264.7 cell growth. Phytomedicine 2014; 21: 1633-7.
143. Liu YQ, Han XF, Liu T, Cheng MC, Xiao HB. A cell-based model of bone remodeling for identifying activity of icarrin in the treatment of osteoporosis. Biotechnol Lett 2015; 37: 219-26.
144. Henriksen K, Thudium CS, Christiansen C, Karsdal MA. Novel targets for the prevention of osteoporosis-lessons learned from studies of metabolic bone disorders. Expert Opin Ther Targets 2015: 1-10.
145. Bromme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs 2009; 18: 585-600.